Biofrontera Inc. Files 8-K on Financial Condition & Operations

TL;DR

**Biofrontera Inc. just dropped an 8-K on its financials, signaling an update on performance.**

AI Summary

Biofrontera Inc. filed an 8-K on January 11, 2024, to report on its current financial condition and operations. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance, which could include recent earnings or operational results. For investors, this matters because it offers a timely glimpse into the company's health and trajectory, potentially influencing stock valuation based on whether the results meet or miss expectations.

Why It Matters

This filing provides investors with an update on Biofrontera Inc.'s financial health, which is crucial for assessing its current performance and future prospects.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the undisclosed financial results it references could carry significant risk depending on their content.

Analyst Insight

Investors should await the actual financial results or operational details that this 8-K refers to, as the filing itself is merely a procedural announcement. Once the details are released, analyze them for impact on revenue, profitability, and future guidance.

Key Numbers

• 2024-01-11 — Date of Report (The date the earliest event reported in this 8-K occurred and the filing date.)
• 001-40943 — Commission File Number (Unique identifier for Biofrontera Inc. with the SEC.)

Key Players & Entities

• Biofrontera Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Biofrontera Inc.
• Woburn, Massachusetts (company) — address of principal executive offices for Biofrontera Inc.
• 001-40943 (dollar_amount) — Commission File Number
• 47-3765675 (dollar_amount) — IRS Employer Identification No.
• 781-245-1325 (dollar_amount) — Registrant's telephone number
• January 11, 2024 (dollar_amount) — Date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 46KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-24-002083.txt ( ) — 290KB
• bfri-20240111.xsd (EX-101.SCH) — 4KB
• bfri-20240111_def.xml (EX-101.DEF) — 27KB
• bfri-20240111_lab.xml (EX-101.LAB) — 37KB
• bfri-20240111_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On January 11, 2024 Biofrontera Inc. (the "Company") issued a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Form 8-K") and is incorporated herein by reference. The information contained in this Item 2.02 in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration specific reference in such filing. The financial information set forth in this Form 8-K reflects the Company's current preliminary revenue estimates, is subject to the completion of its review process, and is subject to change. The Company's fourth quarter results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law. Item 9.01 Financial Statements and Exhibits. 99.1 Press Release dated January 11, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 11, 2024 Biofrontera Inc. (Date) (Registrant) /s/ E. Fred Leffler III E. Fred Leffler III Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR